http://www.thebell.co.kr/free/Content/ArticleView.asp?key=202207081000354600106360&svccode=
The Bell compiled the desarrollo de nuevos fármacos financiamiento details (by payment date) of nacional unlisted pharmaceutical/biotech empresas through the primer semestre of este año, categorized by modality (I+D tecnología) theme. A total of 46 empresas raised KRW 881.8 billion across 19 tecnología themes.
Companies with technologies for inhibiting antigens and specific cells (inhibitors) aseguró the most financiamiento. During this period, a total of 9 empresas (Biopharmsolutions, Spark Biopharma, Immunodesigners, Autotelic Bio, Kine Sciences, First Biotherapeutics, RudaCure, Etnova Therapeutics, and Nextgen Bioscience) raised KRW 163.7 billion.
Inhibitors are a traditional modality with a desarrollo history of over 40 years. They were first comercializard in 2001 when Novartis developed Gleevec, a chronic myelogenous leukemia tratamiento based on BCR-ABL inhibition (EGFR inhibitor) mechanism. In the 2010s, interest in inhibitors waned as more tecnología-intensive modalities took center stage. Recientemente, they han sido drawing renewed attention due to their lower desarrollo costs and seguridad proven by long-term investigación.
